Anteris Technologies Global Corp (ASX: AVR) Reports Q1 2025 Results
Financial Performance
Anteris Technologies Global Corp. reported a 27% decrease in net sales to $0.6 million for Q1 2025, compared to $0.8 million in the same period last year. Operating loss widened by 22% to $21.78 million from $17.78 million. Research and development expenses increased by 42% to $16.46 million.
Use of Proceeds
The company utilized $20.8 million of its $80.0 million IPO proceeds for the ongoing development of the DurAVR® THV system and the preparation and enrollment of the Pivotal Trial. Additionally, $10.5 million was allocated to net working capital and other general corporate purposes, including the repayment of $6.4 million in debt.
Operational Updates
Anteris continues to scale its manufacturing capabilities for the DurAVR® THV system, expanding into new ISO Qualified Clean Room facilities to support the upcoming Pivotal Trial. The company is also sourcing ADAPT® tissue from both the U.S. and Australia to mitigate supply chain risks.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
